BioProspect (BPO) is developing a new paradigm in
psychiatric diagnosis based on Heart Rate Variability (HRV) technology that
utilises human heart rate characteristics, including certain tell-tale changes,
as sensitive measures for depression. The HRV technology consists of a
heart monitor that sends recordings wirelessly to the internet where a
proprietary algorithm analyses and delivers a quantifiable score for depressive
illness.
This innovative technology is non-intrusive, quick, objective, decisive and will revolutionise the diagnosis and treatment of mental health.
The HRV Technology is the first objective, evidence based approach to
the diagnosis of depression and other affective disorders.
Depression is estimated to cost AUS $15 billion annually.
Hi Rae - a most interesting company with an unusual mix of activities ... I look forward to learning more about your company ... and about how useful you find its financial statements in helping you understand what is really going in your firm. :)
ReplyDeleteThanks for your encouragement Martin, very much appreciated. Kind Regards, Rae
DeleteHello Rae, wonder how service delivery is considering you have both natural products then oil, waiting to hear more
ReplyDeleteCheers
Deanna
Hi Rae! Loving your blog and you have such a great company. I also look forward to hearing more about your product in relation to your financial statements. Your company is similar to mine in terms of the need for constant investment in research and innovation so I am interested to see how you discuss these topics. I will be sure to follow for updates.
ReplyDeleteI would love if you could check my blog out also, it evaluated the UK company the British Polythene Industries.
http://laurennewtonacct11059.blogspot.com.au/
Thanks,
Lauren
Great blog! Looking forward to following you!
ReplyDelete